Intrinsiqq
Burzynski Research Institute Inc. logo

Burzynski Research Institute Inc. Quality Score

BZYR

Compare
Quality18

Weak across most dimensions. This doesn't mean avoid, but the burden of proof is on the bull case.

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
0/100
-0.0x

Negative earnings, no valuation support

Business Quality & Capital Allocation

Share Dilution
80/100
0.0%

Roughly flat, no meaningful dilution

Capital Structure
100/100
-$2165

Net cash position, no leverage concern

2022
$3382
$0.00
2023
$934
$0.00
2024
$1310
$0.00
2025
$847
$0.00
TTM
$2165
$0.00
CashDebt
Customize WeightsPremiumUpgrade

Burzynski Research Institute (BZYR) quality: score, margins and returns

Burzynski Research Institute (BZYR) scores 18/100 on Intrinsiqq's quality score (a lower-quality business), a weighted blend of 2 metrics each scored 0 to 100. Every metric is computed from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Burzynski Research Institute (BZYR) a high-quality business?+

Burzynski Research Institute scores 18 out of 100 on Intrinsiqq's quality score, a weighted blend of 2 metrics each scored 0 to 100, which rates it a lower-quality business on these measures. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does Burzynski Research Institute's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from BZYR's SEC filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Burzynski Research Institute scores well and where it falls behind.

How the market compares: US profitability statistics

SourceQuality score computed from the 10-Q filed 13 Jan 2026, covering the period ending 30 Nov 2025, as reported to the SEC. Data last refreshed 23 Sept 2026. How this is calculated.

Fiscal year ends Feb. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.

Peers

In Vitro & In Vivo Diagnostic Substances · Pick stocks to compare with BZYR

CompareIntrinsic value
BMRABiomerica Inc.
$1.08-1.82%25
AWHLAspira Women's Health Inc.
No recent price0
ICCCImmuCell Corporation
$10.92-2.24%69
VNRXVolitionRx Limited
$0.16+0.00%30
IMDXInsight Molecular Diagnostics Inc.
$1.96+18.07%25
CDIOCardio Diagnostics Holdings Inc.
$1.60-3.03%30
QDELQuidelOrtho Corporation
$8.32-6.73%0
NTLAIntellia Therapeutics Inc.
$10.00+5.04%25

Spot a number that looks wrong? Check it in BZYR's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing BZYR

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.